VPTDF - Ventripoint Announces Sponsorship for the European Society of Cardiology Congress 2022
(TheNewswire)
Toronto, Ontario – TheNewswire –August 26, 2022 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is excited to announce that it will be exhibitingat the 70 th European Society of Cardiology (ESC) Congress, which will beheld in Barcelona, Spain from August 26-29, 2022
The spotlight in 2022 is “Cardiac imaging”, evermore important in cardiovascular medicine with its profoundimplications from prevention to diagnosis, clinical decision-making,guiding of interventions and follow-up of therapeutic procedures.
The Congress website ( http://esc2022-congress.org/ ) reports 40,000 participants from 170 countries will hear5,000 medical presentations during the congress. For the first time,the ESC Conference will be held virtually and in person, providingaccess to the latest cardiology research and clinical updates fromanywhere in the world.
The ESC is comprised of clinicians, scientists, andother professionals in the cardiology field. The ESC aims to unitenational cardiac societies from around the world to further study andunderstand cardiovascular disease.
This is another opportunity for Ventripoint to informthe cardiology community about its innovative VMS+ products andfollows on the heels of the successful AEPC conference this past Mayin Geneva (see NR May 17, 2022) and the ASE conference in June inSeattle (see NR June 7, 2022). In addition to Ventripoint’s directsales team, our European distributor for Europe, AngioPro, will bejoining us in the exhibition booth to connect with new potentialcustomers and existing users.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS+ products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2022 TheNewswire - All rights reserved.